A recent study on arXiv highlights the potential of TabPFN (Tabular Pre-Trained Foundation Network) in predicting the conversion from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD) within three years, achieving an AUC of 0.892 on the TADPOLE dataset from ADNI, even in low-data scenarios (N=50) where traditional models like XGBoost and Random Forest falter. The study by Bulent Soykan et al. demonstrates TabPFN’s edge over conventional machine learning approaches, particularly in data-limited settings common to rare disease research and under-resourced healthcare systems. Using multimodal biomarkers—demographics, APOE4 status, MRI volumes, CSF markers, and PET imaging—TabPFN consistently outperformed competitors like LightGBM (AUC=0.860) across training set sizes from 50 to 1,000. This suggests that foundation models, pre-trained on diverse datasets, can adapt to sparse medical data, a critical advantage for conditions like AD where longitudinal data is scarce due to slow disease progression and high study costs. Beyond the technical results, this research underscores broader challenges in medical AI, often overlooked in mainstream coverage. Ethical concerns arise around deploying such models in clinical settings without robust validation across diverse populations, as the TADPOLE dataset may not fully represent global demographics. Additionally, while TabPFN’s performance is promising, practical integration into healthcare workflows remains unaddressed—issues like model interpretability and regulatory hurdles under FDA or EMA guidelines are critical but absent from the study. Drawing on related work, such as the 2022 Nature Medicine paper on AI diagnostics (https://www.nature.com/articles/s41591-022-01937-z), and the 2021 WHO report on AI ethics in health (https://www.who.int/publications/i/item/9789240029200), the field must prioritize transparency and equity to prevent bias amplification in already underserved regions.